FDA suspends license for Valneva’s chikungunya shot
The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to conclude the vaccine is no longer safe for its intended use.
Previous Post
Clonally Expanded CD8+ T Cells May Play Role in Alopecia Areata
Next Post
STAT+: FDA pulls biologics license for chikungunya vaccine
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago